Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19Virology Published on 2020-06-092022-10-30 Journal: Journal of Clinical Microbiology [Category] COVID-19, SARS, [키워드] acute respiratory syndrome addition Amplicon cause characterized clinical coronavirus coronavirus disease correlation COVID-19 culturability Culture detect detectable examined Genome genome copy genome integrity Infectivity linear log lowest N genes Nasopharyngeal swab nine Nsp12 performed positive Potential real-time RT-PCR Region regions required reverse transcription-PCR RT-PCR SARS-CoV-2 SARS-CoV-2 RNA specimen specimens sputum viral genome Viral RNA virus virus isolation was determined [DOI] 10.1128/JCM.01068-20 PMC 바로가기 [Article Type] Virology
Evaluation of modelling study shows limits of COVID-19 importing risk simulations in sub-Saharan AfricaLetter to the Editor Published on 2020-06-092022-11-01 Journal: Epidemiology and Infection [Category] COVID-19, SARS, [키워드] 2019-nCoV Asymptomatic case Characteristics China coronavirus disease country COVID-19 COVID-19 case Effectiveness epidemiological data investigated limit Mathematical modelling Nigeria not express Novel coronavirus Precision Region reported researcher risk South Spread SSA sub-Saharan Africa Symptoms the patient Transmission Travel virus [DOI] 10.1017/S095026882000120X PMC 바로가기 [Article Type] Letter to the Editor
Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping ReviewReview Published on 2020-06-082022-10-31 Journal: Nutrients [Category] COVID-19, SARS, [키워드] acute respiratory syndrome Administered analyzed Bacterial benefit clinical trial conducted coronavirus coronavirus disease COVID-19 diet dosages drug effective effort endothelial damage Evidence global pandemic immune response Infection interfere molecular nutraceutical nutraceuticals pandemic Pathways Probiotics reducing Regulatory respiratory viruses review risk Safe SARS-CoV-2 Scientific community Side effect Spread Supplementation Support symptoms of COVID-19 systemic inflammation tested Vaccine virus [DOI] 10.3390/nu12061718 PMC 바로가기 [Article Type] Review
Immunization with porcine epidemic diarrhea virus harbouring Fc domain of IgG enhances antibody production in pigsResearch Article Published on 2020-06-082022-10-28 Journal: The Veterinary Quarterly [Category] Coronavirus, MERS, [키워드] addition Analysis antibody production Cell collected coronavirus crossbred cytokine domain Efficacy ELISA ENhance epidemic diarrhea evaluated experiment expressing facilitate Fc IFN-γ IgG IgG Fc immune response immunization inactivated Inactivated vaccine Infection intramuscularly negative controls Neutralizing objective PEDV Porcine Porcine epidemic diarrhea Prevent Protective Result resulting sera serum serum sample significantly higher significantly increased Spread swine t-test TCID two-tailed Vaccine vaccine candidate Vero Cell virion virus was performed were used [DOI] 10.1080/01652176.2020.1773006 PMC 바로가기 [Article Type] Research Article
Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)Original Article Published on 2020-06-082022-10-30 Journal: Infection Control and Hospital Epidemiology [Category] COVID-19, SARS, [키워드] aerosol aerosol-generating procedure analyzed Asymptomatic change clinical sample Cohort contamination rate coronavirus disease correlation COVID-19 COVID-19 patient COVID-19 patients detectable Frequently gelatin highest hospitalized patient hygiene Infection infection control Isolation room Mask measure Median viral load Patient patients polymerase chain positive predominant remains uncertain Respiratory Coronavirus RT-PCR sampling SARS-CoV-2 SARS-CoV-2 RNA surgical symptomatic Transmission transmission of SARS-CoV-2 Viral load virus was performed wearing [DOI] 10.1017/ice.2020.282 PMC 바로가기 [Article Type] Original Article
Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-06-082022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 6 hour activity Analysis Antiviral effect blinded Chloroquine Complication contraindication Control control group COVID-19 COVID-19 patient COVID-19 PCR test COVID-19 positive patient Date death determine Diabetes Mellitus dissemination dose Dual therapy Efficacy element Elimination expected Follow-up greater Hospital admission hospital discharge Hydroxychloroquine hypertension inherent Intervention Intubated invasive mechanical management Mechanical mechanical ventilation medication MERS monotherapy nitazoxanide number obesity objective Older outcome parallel group participant Patient patients with COVID-19 PCR test percentage Placebo positive patients Presence protocol QT interval QTc randomised randomised controlled trial Randomized Randomly reached receive recruited recruitment reducing required risk factor Sample size SARS-CoV-2 sealed Seven state status Study protocol therapy Toluca treat treated Treatment treatment regimen Trial Ventilation ventilatory support virus website [DOI] 10.1186/s13063-020-04448-2 PMC 바로가기 [Article Type] Letter
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trialLetter Published on 2020-06-082022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 48 hour 48 hours Activation Administered adverse event African age allergy analyzed Angola Antiviral approved ARMS Barcelona baseline blinded block Cerebrovascular disease chain chest X-ray childbearing chronic clinical care clinical trial co-morbidity conducted contraceptive method control group coronary disease cough country COVID-19 COVID-19 disease COVID-19 patient criteria Critical current CYP3A4 death detectable determine diagnosed with COVID-19 disease dissemination dose double-blind drug early treatment Efficacy element Endemic EudraCT excluded eye Factor Fever flow cytometry Follow-up visit Frequency Gabon global health groups history home visit Identified IgA IgA level IgG IgM immune response Immunity immunology immunomodulatory IMPROVE in vivo Infection Inflammatory inhibitor interfere investigator involved Isolation Ivermectin laboratory parameter Loa loa magnitude marker median Nasopharyngeal swab nasopharyngeal swab PCR negative neoplasm Nigeria no risk number objective outcome participant Patient Patient care patients PCR PCR cycle physical Placebo placebo group placebo-controlled Pneumonia positive positive SARS-CoV-2 PCR post-menopausal Potential pregnancy test pregnant women progression proportion protocol public health pulmonary random randomised randomised controlled trial randomization randomization list Randomized Rapid diagnostic test reaction receive recent recruited reduce Registered renal resident risk Ritonavir Safe Sample size SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific T cell secondary sequence Seroconversion severe disease severity single center single dose Spain status Study protocol subject submitted surgical Symptom symptom onset the patient the SARS-CoV-2 threshold transcriptomics Transmission transmission-blocking Travel treated patient treated patients Treatment treatment group Trial unblinding Viral load virus vulnerable population website with mild disease women [DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter
Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality controlReview Published on 2020-06-082022-10-31 Journal: Electrophoresis [Category] COVID-19, SARS, [키워드] acute respiratory syndrome adjuvants approach approval average buffer centrifugation competent condition conditions coronavirus COVID‐19 downstream Effects epitope example feasible Formulation immunologically inactivation information knowledge membranes Physicochemical properties Protein Quality control Radiation rigidity SARS‐CoV‐1 SARS‐CoV‐2 SARS‐CoV solvent stability Support susceptibility temperature transfer UV light Vaccine Vaccine development virus virus inactivation [DOI] 10.1002/elps.202000121 PMC 바로가기 [Article Type] Review
Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication CycleAntiviral Agents Published on 2020-06-082022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19, [키워드] 50% effective concentration acute respiratory syndrome antiparasitic drug Antiviral agents antiviral drug benefit binding Calu-3 Cell Cell culture coronavirus COVID-19 COVID-19 patients cycle drug Drug repurposing epithelial epithelial cell line human lung human serum impacted Infection inhibit inhibited log pandemic performed Plaque reduction assay Prevent primary human airway progression provide public health randomized clinical trials Registered Replication SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 replication step Suramin treat treated Vero E6 cell Viral load virus Wuhan, China [DOI] 10.1128/AAC.00900-20 PMC 바로가기 [Article Type] Antiviral Agents
ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2Evolutionary Genetics Published on 2020-06-082022-10-31 Journal: Genetics and Molecular Biology [Category] COVID-19, [키워드] ACE2 ACE2 binding site Analysis catalytic domain contribute coronavirus COVID-19 Critical difference evolutionary dynamics Factors Genetic Genomic analysis hosts human populations humans identify infect infecting Infection innate immune responses inter and intra-species diversity mammal membrane protein Mortality natural selection New coronavirus orthologue pandemic of COVID-19 performed placental placental mammals polymorphism Positive selection rate of infection responsible reveal SARS-CoV-2 selected trajectory Variation virus [DOI] 10.1590/1678-4685-GMB-2020-0104 PMC 바로가기 [Article Type] Evolutionary Genetics